{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:19Z","timestamp":1793939419640,"version":"4.8.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.autrev.2025.103761","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T02:09:17Z","timestamp":1738289357000},"page":"103761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: How to correctly diagnose the two"],"prefix":"10.1016","volume":"24","author":[{"given":"Fengna","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103761_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103761_bb0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis Spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2025.103761_bb0015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.4103\/0972-2327.164816","article-title":"Neuromyelitis optica spectrum disorders: an update","volume":"18","author":"Pandit","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0020","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103761_bb0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis Optica Spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103761_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102218","article-title":"The 2015 IPND criteria increases the yield in diagnosis of Neuromyelitis Optica Spectrum disorder in Thai patients compared to the 2006 diagnostic criteria","volume":"43","author":"Rattanathamsakul","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103761_bb0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2025.103761_bb0050","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/0004-282X20140032","article-title":"Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesi","volume":"72","author":"Sato","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.autrev.2025.103761_bb0055","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Contentti","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103761_bb0060","doi-asserted-by":"crossref","first-page":"104730","DOI":"10.1016\/j.msard.2023.104730","article-title":"T. Brazilian Committee for and S. Research in Multiple, Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients","volume":"75","author":"Lana-Peixoto","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103761_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102921","article-title":"Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges","volume":"21","author":"Liu","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103761_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200188","article-title":"Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder","volume":"11","author":"Carta","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103761_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica study group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-94-024-1057-0_1","article-title":"Molecular biology of Aquaporins","volume":"969","author":"Li","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2025.103761_bb0085","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","article-title":"Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica","volume":"70","author":"Matiello","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/brain\/awab311","article-title":"Emerging roles for dynamic aquaporin-4 subcellular relocalization in CNS water homeostasis","volume":"145","author":"Salman","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2025.103761_bb0095","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","article-title":"The glymphatic pathway in neurological disorders","volume":"17","author":"Rasmussen","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.molmed.2019.11.008","article-title":"Glymphatic system impairment in Alzheimer\u2019s disease and idiopathic Normal pressure hydrocephalus","volume":"26","author":"Reeves","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2025.103761_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw3210","article-title":"An ocular glymphatic clearance system removes \u03b2-amyloid from the rodent eye","volume":"12","author":"Wang","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103761_bb0110","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103761_bb0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","article-title":"Updates in NMOSD and MOGAD diagnosis and treatment: a tale of two central nervous system autoimmune inflammatory disorders","volume":"42","author":"Cacciaguerra","year":"2024","journal-title":"Neurol Clin"},{"key":"10.1016\/j.autrev.2025.103761_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-94-024-1057-0_16","article-title":"Aquaporin-targeted therapeutics: state-of-the-field","volume":"969","author":"Tradtrantip","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2025.103761_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00281-022-00941-9","article-title":"Immuno-pathogenesis of neuromyelitis optica and emerging therapies","volume":"44","author":"Chihara","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2025.103761_bb0130","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103761_bb0135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103761_bb0140","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0145","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.autrev.2025.103761_bb0150","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/WNL.0b013e318211c379","article-title":"CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG","volume":"76","author":"McKeon","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103761_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5339\/qmj.2022.29","article-title":"Seropositive Neuromyelitis Optica in a case of undiagnosed ankylosing spondylitis: a neuro-Rheumatological conundrum","volume":"2022","author":"Ghosh Md","year":"2022","journal-title":"Qatar Med J"},{"key":"10.1016\/j.autrev.2025.103761_bb0160","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103761_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.635419","article-title":"Anti-aquaporin 4 IgG is not associated with any clinical disease characteristics in Neuromyelitis Optica Spectrum disorder","volume":"12","author":"Schmetzer","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0170","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica Spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103761_bb0175","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sepulveda","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103761_bb0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of Neuromyelitis Optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103761_bb0185","doi-asserted-by":"crossref","unstructured":"J.W. Hyun, I.H. Jeong, A. Joung, S.H. Kim and H.J. Kim, Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder, Neurology 86 (2016) 1772\u20139.","DOI":"10.1212\/WNL.0000000000002655"},{"key":"10.1016\/j.autrev.2025.103761_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577506","article-title":"The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: experience with 461 cases from a single Centre in South China","volume":"353","author":"Li","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103761_bb0195","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 Diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103761_bb0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12974-022-02450-w","article-title":"CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage","volume":"19","author":"Hyun","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2025.103761_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jnnp-2012-302925","article-title":"South Japan multiple sclerosis genetics, distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status","volume":"84","author":"Yoshimura","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103761_bb0215","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.autrev.2025.103761_bb0220","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.nrl.2020.08.018","article-title":"Neuromyelitis optica spectrum disorder: Do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective","volume":"38","author":"Ortiz Salas","year":"2023","journal-title":"Neurologia (Engl Ed)"},{"key":"10.1016\/j.autrev.2025.103761_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum Neurofilament light and GFAP are associated with disease severity in inflammatory disorders with Aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103761_bb0230","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103761_bb0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","article-title":"Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review","volume":"19","author":"Schindler","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103761_bb0240","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/cei\/uxad053","article-title":"Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?","volume":"213","author":"Chu","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103761_bb0245","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/jnnp-2019-322286","article-title":"CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD","volume":"91","author":"Kleerekooper","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103761_bb0250","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a Neuromyelitis Optica Spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0255","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/jnnp-2022-330707","article-title":"Anti-Argonaute antibodies as a potential biomarker in NMOSD","volume":"94","author":"Carta","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103761_bb0260","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2023.2523","article-title":"Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination","volume":"80","author":"Gomes","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2025.103761_bb0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s42466-021-00129-w","article-title":"Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA\/anti-SOX1 and VGCC antibodies","volume":"3","author":"Feldheim","year":"2021","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.autrev.2025.103761_bb0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cytogfr.2023.12.007","article-title":"Navigating IL-6: from molecular mechanisms to therapeutic breakthroughs","volume":"76","author":"Swaroop","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2025.103761_bb0275","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200173","article-title":"Long-term effects of IL-6 receptor blockade therapy on regulatory lymphocytes and neutrophils in Neuromyelitis Optica Spectrum disorder","volume":"11","author":"Matsuoka","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103761_bb0280","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2019.01.015","article-title":"The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders","volume":"330","author":"Monteiro","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103761_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11064-013-1199-5","article-title":"A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra","volume":"39","author":"Rae","year":"2014","journal-title":"Neurochem Res"},{"key":"10.1016\/j.autrev.2025.103761_bb0290","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fnagi.2015.00202","article-title":"Probing astrocyte metabolism in vivo: proton magnetic resonance spectroscopy in the injured and aging brain","volume":"7","author":"Harris","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.autrev.2025.103761_bb0295","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000626","article-title":"Classifying the antibody-negative NMO syndromes: clinical, imaging, and metabolomic modeling","volume":"6","author":"Yeo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103761_bb0300","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1177\/13524585221115304","article-title":"Relapsing antibody-negative patients with features of neuromyelitis optica spectrum disorders: differences in N-acetylaspartate level in the cervical spinal cord indicate distinct underlying processes","volume":"28","author":"Kossowski","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103761_bb0305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103761_bb0310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/0004-282x20160193","article-title":"Neuromyelitis optica: phenotypic characteristics in a Brazilian case series","volume":"75","author":"Del Negro","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.autrev.2025.103761_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102208","article-title":"Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort","volume":"44","author":"Edgar Patricio","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103761_bb0320","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T13:37:17Z","timestamp":1740922637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1568997225000217"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103761","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: How to correctly diagnose the two","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103761"}}